TNXP Tonix Pharmaceuticals Holding Corp

$TNXP New long position in Tonix Pharma today. This is another one caught in the same biotech flush that's taken out nearly everything in the space this past month. The stock is down about 45% over that stretch and is sitting a few cents above its 52-wk low. This isn't a pre-revenue science project, though. Tonix has three FDA-approved products on the market. The lead is TONMYA, the first new fibromyalgia drug in over 15 yrs, which launched last Nov and nearly tripled net sales Q over Q in Q2. Behind the commercial biz sits a deeper pipeline than the valuation implies. TNX-102 SL, the same molecule as TONMYA, is in Phase 2 for both major depressive disorder and acute stress disorder, with ASD topline data guided for 1Q'27. Beyond that: TNX-1300 in mid-Phase 2 for cocaine intoxication, TNX-4800 for Lyme disease prevention heading into a Phase 2 field study, TNX-1500 for transplant rejection, and TNX-2900 for Prader-Willi, which carries FDA Orphan Drug and Rare Pediatric Disease designations. The bal sheet is what initially caught my eye. Tonix had $176.2M in cash at 6/30 and no debt, against a MC of roughly $92M. Haircut that for a full quarter of burn and the stock is still trading well below cash. The market is pricing the commercial biz and the PL at less than zero. Technicals on my screen... • RSI(14) at 18.9, pinned in oversold territory for most of Oct • Slow stochs hooking up off the floor, %K crossing over %D • ADX north of 60 shows how one-sided the selling has been, but readings that stretched tend to show up late in a move, not early • Volume has dried up the last several sessions as price tightens just above the low Levels I'm watching... • $5.01: 52-wk low • $6.55: 20-day SMA, first real test on any bounce • $9.83: 50-day SMA • $10.77 / $12.58: 100-day and 200-day SMAs Q3 numbers hit Nov 9 before the open. TONMYA script trends and an updated cash figure are what matter to me. All told, I took a 1/3 position in the low $5S this morning. The sizing is deliberate. This is a commercial launch that is still burning cash, and the Street likely wants to see the runway extended before it pays up, so I'm leaving room to add. At a neg EV with approved products already generating revs, I really like the risk/reward from here. As always, I'm just sharing my work here. DYOR and check everything. NFA.

$TNXP The announcement of ER on 11/09 means that either a lawsuit against Dr. Reddy is about to file. The lawsuit will trigger a 30 month exclusivity where the FDA cannot approve the Dr. Reddy's ANDA. As such, Tonix will have exclusitivity until mid 2029. I looked over the four patents on the eutectic formulation of Tonya. The science and the claims are strong. It will be hard for Dr. Reddy to prove that this formulation is "obvious". However, given the cost and onerous conduct of a trial, I think that there will be strong incentive for both sides to settle. Most likely for a generic starting in 2031 or 2032, a few years ahead of 2034 when the patents expire. In any case, I expect news on the lawsuit later this week or some time next week. This will remove much uncertainty on the Tonmya revenue stream for the next few years which led to the current PPS. The current PPS is ridiculous given what we know about Tonmya script growth. This will change soon.

$TNXP Seth, investors in Tonix would welcome more information at quarterly earnings reports. Providing more information in the areas outlined below will combat the fear and ignorance which has pounded the stock price over the last year. Patent uncertainty. Has Tonix filed a lawsuit against Dr Reddy? How does Tonix plan to defend against claims of invalidity and non-infringement? Revenue uncertainty. What is Tonix growth strategy for the second year of Tonmya? Is Tonix pursuing partnerships to expand geographic reach of Tonmya? When will Tonix provide revenue forecasts? Expense uncertainty. Is Tonix planning to reduce expenses to conserve cash? Is Tonix measuring performance of individual sales contractors and rotating out poor performers? How much has Tonix budgeted for patent lawsuit and manufacturing facility? Overall, what is Tonix strategy for managing cash until it achieves breakeven? What conditions must be met for Tonix to stop issuing more shares?

$TNXP bla bla bla… management Bla bla bla… patent challenge Bla bla bla… jUsT CyCLobEnZAprInE Bla bla bla… dilution Bears keep sounding like a broken record. Sit back and relax Longs. Sales and revenue are increasing. Pipeline is developing. Read the sec files and see for yourself. GLA.

$TNXP MASSIVE EARNINGS COMING UP 🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀 HUGE MARKET SHARE, SUBSTANTIAL IMPROVEMENT IN DRUG ACCESSIBILITY, 100-300% PRICE ACTION NEXT WEEK 🚀🚀🚀🚀🚀🚀🚀🚀

$TNXP BIG BOYS LOADING UP Essex Investment Management Co Llc Increased their holdings by 77.06% to 292,397 shares

$TNXP Another update on the retail trading activity for the past 2 weeks; apologies for missing last week! Below are the net flows of retail traders - Institutions will be coming soon! 22nd October - $16.2K 21st October - $127.1K 20th October - $36.5K 19th October - $83.6K 16th October - $20.2K 15th October - $24.6K 14th October - ($3.4K) 13th October - $27.8K 12th October - $24.2K Retail has had $283.7K net flows over the past 5 days, showing a good amount of accumulation of the stock. More to follow next week!

$TNXP My view is that the next couple of quarters are particularly important. Tonix has paid to establish the commercial infrastructure and secure access; now it needs to demonstrate that those investments translate into sustained prescription and revenue growth. Tonix reported $35.96M of SG&A in Q2 2026, compared with $16.20M in Q2 2025, an increase of $19.76M, or 122%. Driver of increase Q2 2026 vs Q2 2025 Sales and marketing +$13.8M Employee-related expenses +$3.8M Professional expenses +$1.9M Total increase +$19.5M The agreements create the opportunity for more prescriptions, but Tonix still needs to spend money to convert that access into actual sales. In its Q2 results, Tonix specifically said it planned to add 50 sales representatives, taking its field force to approximately 150 by September 2026. It also said it expected the benefits of the new payer agreements to begin materialising in Q3 and Q4.

$TNXP Think the biggest problem many have in whats called the 'market' is that so many stocks are WAY overvalued, have nothing to justify it, yet are cause many are ignoring they are buying junk. While TNXP is being forced to 'show us' first. Current market cap of around $90 Mil (17.2 mil shares IF this is still an accurate #) What can they justify IF they can get 250,000 users? 250,000 x $1800/month x 12 months = approx $5.4 Billion in 'sales' Say they only capture 25% of that after taxes, losses to the others involved in the sales/manufacturing/distribution, et al or approx $1.3 Billion in profits Should be able to justify a $1 Bill market cap? Thats 10X the current share price. And thats just 1/8 of the people suffering with a confirmed fibro diagnosis. And on a side note? Been a wondering if the company is getting quietly pressured to sell out by one of the big pharmas who have to be aware of this drugs potential IF it not only works, but works effectively for a long time..

$TNXP The market cap today is just slightly over 50% of cash on hand. This means that Tonmya is being evaluated at a negative value. However, we know now that Tonmya revenue has been increasing quickly: Q1 $3.7M, Q2 $11.0M, and Q3 ~$15M. My model says that Q3 data perfectly tracked the growing TRx script numbers that were publishing. Patient need is a fundamental that is independent of stock price. IMO, the PPS drop from around $13 to just about $5.20 now is due to a mistaken belief that Tonmya is going generic due to the Reddy ANDA and patent challenge. This is wrong. First, Tonix will file a lawsuit against Reddy soon. That will immediately gain them market exclusivity at least to near mid-2029. Second, Reddy could win only by showing that the eutectic formulation of Tonmya is obvious. That's a very hard challenge to the four patents in play. IMO, news about the lawsuit will come soon. The stock will be rerated once people realize/see that.

$TNXP This isn't normal; there is simply someone pushing the stock down—perhaps large investment firms that are going to...

$TNXP Remember a couple of things. Over 85% of speculative/clinical stage bio companies never see their product reach FDA approval. TNXP did To reach a milestone like that destroys investors. It's why nobody invests long term in them. They swing them. Common knowledge Then once miraculously approved, they now have to survive at least a year of commercializations stages which costs the company $100's of millions to get through as they fight through the red tape of insurance uptake and demand. While 50%-60% meet expectations, investors still get hurt due to the money spent. Around 35%-40% underperform expectations. 10% or so fall on their face. Whatever way happens, investors will always lose money because the spend is more then the revs. Is the stock investable in this stage? Maybe. Each is a snowflake at this point. TNXP is exceeding expectations for Tonmya. But they are spending like a drunken sailor to do it. Is the current pps fair? Or is it over blown? You decide

$TNXP Are the anti-TNXP gloaters retards? Some might actually be. But the sick part is how some gloat over the falling share price, knowing its causing some misery, suffering and in some cases, forcing them to take real losses. So are these folks retards or just frigging idiots who love to pile onto others misery cause of their own twisted mental make up? . I suspect its because some enjoy being able to harass others just because they can. Yep, these kind of folks are really on the low end of the human totem pole aren't they when it comes to the kind of people you really want to be associating with.

$TNXP last 2 days quiet accumulation by cleaning out weak. Spike will come suddenly and may be very brutal for shorts. Time will tell.

$TNXP It's a classic short-seller tactic to discredit the CEO. But here, longs are doing it. As if this guy doesn't have a stake. Stop expecting companies to care about short-term price movements. This company is building for the long term. IMO, the stock will soar after 1) Dr. Reddy's Laboratories' patent attack is rebuffed and 2) a string of earnings reports proves out the company's execution.

$TNXP just speaking up for those of us…who lost, but who plan to hold this bag until it gets back above 30…yeah, I made a mistake, but I bet real money that the best course is to hold it.

$TNXP Very optimistic about return to 20$ or so, Not sure yet about 50-70$ dream. Even if we break even, do we think seth will just stop the madness or double down? there is not such thing as enough money, if you can have drug revenue money and investor money aswell?

$TNXP The sales are doing well. There is no other drug like it available, they just share the main ingredient. Can't take flexeril or any others long term and they have nasty sides. Can take Tonmya long term and a lower dose does more. Delivery matters. Generics challenge blockbuster drugs. Tonix will fire back in 45 days and get the stay. Not outside the norm on a new drug. Guys really working to get that FUD

$TNXP Cash on hand $9.42. Trading at $5.67. Seth is an idiot. Needs to buy 2-3 mil shares down here and file. Still a chance to create a monster short squeeze.

$TNXP Have a good and blessed week—a week of hope as we await the takeoff we have all been longing for for such a long time. Be cautious when "averaging down" (buying more to lower your average cost); do so only after clear signs of an upward trend. Crossing the $9 mark would certainly be a strong signal to resume buying on a large scale. This is just my opinion, of course—everyone should do as they see fit.